{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:11:02Z","timestamp":1794269462514,"version":"4.9.0"},"reference-count":33,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Menwell Ltd","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjph"],"accepted":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Obesity is a critical public health challenge globally. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in weight loss; however, their adoption is influenced by various individual and societal factors. This study sought to examine awareness, motivations and barriers to adoption of GLP-1RAs in the UK, with a focus on demographic differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional survey of 1297 UK adults was conducted using an electronic questionnaire distributed via social media, online platforms and personal networks. The survey assessed demographic characteristics, awareness, perceptions and use of GLP-1RAs. Data were analysed using \u03c72 and Kruskal\u2013Wallis tests. The primary analysis method was ordinal logistic regression, with multinomial logistic regression used to estimate the relative risk ratio (RRR) if the proportional odds assumption was violated. A p-value&lt;0.05 was considered significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significantly higher awareness of GLP-1RAs was observed among those attempting weight loss in the past year (85.7% vs 14.3%, p&lt;0.001). Women were more likely to report both awareness (87.2% vs 68.2%, p&lt;0.001) and excellent understanding (20.0% vs 7.5%, p&lt;0.001). Main information sources included news (60.1%) and social media (50.3%). Only 9.0% first learnt about GLP-1RAs from healthcare providers. Past and current users were less likely than non-users to express scepticism about safety and efficacy and 6.91 times more likely to strongly disagree (compared with being neutral) that \u2018risks outweigh the benefits\u2019 (RRR, 6.91; 95%\u2009CI, 4.32 to 11.05; p&lt;0.001) and 7.33 times more likely to strongly disagree (relative to being neutral) that \u2018there is not enough evidence to suggest GLP-1RAs are safe\u2019 (RRR, 7.33; 95%\u2009CI, 4.05 to 13.27; p&lt;0.001). 91.0% of current or past users indicated they would recommend GLP-1RAs to a friend struggling with weight management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Concerns about safety, cost and potential side effects remain significant barriers to GLP-1RA adoption. Current or past users strongly disagree with statements of scepticism; however, scepticism among non-users highlights the need for improved public education around safety and efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjph-2024-002519","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T04:10:43Z","timestamp":1753243843000},"page":"e002519","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UK"],"prefix":"10.1136","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8583-0792","authenticated-orcid":false,"given":"Nadja","family":"Auerbach","sequence":"first","affiliation":[{"name":"Menwell Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian N","family":"Liu","sequence":"additional","affiliation":[{"name":"Menwell Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Roy","family":"Huang","sequence":"additional","affiliation":[{"name":"Menwell Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley Kieran","family":"Clift","sequence":"additional","affiliation":[{"name":"Menwell Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Al-Ammouri","sequence":"additional","affiliation":[{"name":"Self-Care Academic Research Unit (SCARU), Imperial College London School of Public Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austen","family":"El-Osta","sequence":"additional","affiliation":[{"name":"Self-Care Academic Research Unit (SCARU), Imperial College London School of Public Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2026010703055639000_3.2.e002519.1","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0140-6736(18)32537-6","article-title":"Time for a new obesity narrative","volume":"392","author":"Ralston","year":"2018","journal-title":"The Lancet"},{"key":"2026010703055639000_3.2.e002519.2","unstructured":"World Health Organisation . Obesity and overweight. 2024."},{"key":"2026010703055639000_3.2.e002519.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2016.04.004"},{"key":"2026010703055639000_3.2.e002519.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045616","article-title":"Changing the narrative around obesity in the UK: a survey of people with obesity and healthcare professionals from the ACTION-IO study","volume":"11","author":"Hughes","year":"2021","journal-title":"BMJ Open"},{"key":"2026010703055639000_3.2.e002519.5","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.102"},{"key":"2026010703055639000_3.2.e002519.6","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2009.159491"},{"key":"2026010703055639000_3.2.e002519.7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026010703055639000_3.2.e002519.8","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12384"},{"key":"2026010703055639000_3.2.e002519.9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206038"},{"key":"2026010703055639000_3.2.e002519.10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7326\/M24-0019","article-title":"Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis","volume":"177","author":"Yeo","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026010703055639000_3.2.e002519.11","unstructured":"National Institute for Healthcare Excellence . Guidance. 2024. Tirzepatide for managing overweight and obesity [ID6179]."},{"key":"2026010703055639000_3.2.e002519.12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2147\/PPA.S212046","article-title":"The impact of personal and cultural beliefs on medication adherence of patients with chronic illnesses: a systematic review","volume":"13","author":"Shahin","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"2026010703055639000_3.2.e002519.13","doi-asserted-by":"crossref","unstructured":"Craig H , Roux CL , Alsaeed D , et al . Factors that determine patients considering medication for the disease of obesity: an imi2 sophia study. Int J Obes [Preprint] 2024. doi:10.21203\/rs.3.rs-3789071\/v1","DOI":"10.21203\/rs.3.rs-3789071\/v1"},{"key":"2026010703055639000_3.2.e002519.14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.12927\/hcpap.2019.26031","article-title":"Value in Healthcare and the Role of the Patient Voice","volume":"18","author":"Gilmore","year":"2019","journal-title":"Healthc Pap"},{"key":"2026010703055639000_3.2.e002519.15","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200623030-00002"},{"key":"2026010703055639000_3.2.e002519.16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.pec.2019.02.022","article-title":"Health beliefs and medication adherence in patients with hypertension: A systematic review of quantitative studies","volume":"102","author":"Al-Noumani","year":"2019","journal-title":"Patient Educ Couns"},{"key":"2026010703055639000_3.2.e002519.17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"The Lancet"},{"key":"2026010703055639000_3.2.e002519.18","unstructured":"STATA v18. n.d. Available: https:\/\/www.stata.com\/stata-news\/news38-2\/"},{"key":"2026010703055639000_3.2.e002519.19","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.6.3.e34","article-title":"Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES)","volume":"6","author":"Eysenbach","year":"2004","journal-title":"J Med Internet Res"},{"key":"2026010703055639000_3.2.e002519.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2026010703055639000_3.2.e002519.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"2026010703055639000_3.2.e002519.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0314407","article-title":"Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study","volume":"19","author":"Abutaima","year":"2024","journal-title":"PLoS One"},{"key":"2026010703055639000_3.2.e002519.23","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00404-023-07367-0","article-title":"Obesity management: sex-specific considerations","volume":"309","author":"Kantowski","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"2026010703055639000_3.2.e002519.24","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02196-z"},{"key":"2026010703055639000_3.2.e002519.25","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-024-00566-z","article-title":"Using large language models to assess public perceptions around glucagon-like peptide-1 receptor agonists on social media","volume":"4","author":"Somani","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"2026010703055639000_3.2.e002519.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101182","article-title":"Trends in Glucagon-Like Peptide-1 Receptor Agonist Social Media Posts Using Artificial Intelligence","volume":"3","author":"Javaid","year":"2024","journal-title":"JACC Adv"},{"key":"2026010703055639000_3.2.e002519.27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and\/or Type 2 Diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026010703055639000_3.2.e002519.28","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"key":"2026010703055639000_3.2.e002519.29","doi-asserted-by":"crossref","unstructured":"Kukhareva PV , Facelli JC , O\u2019Brien MJ , et al . Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis. medRxiv 2024. doi:10.1101\/2024.10.28.24316312","DOI":"10.1101\/2024.10.28.24316312"},{"key":"2026010703055639000_3.2.e002519.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2004.30143.x"},{"key":"2026010703055639000_3.2.e002519.31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5993\/AJHB.34.1.3","article-title":"Barriers to health care access in 13 Asian American communities","volume":"34","author":"Lee","year":"2010","journal-title":"Am J Health Behav"},{"key":"2026010703055639000_3.2.e002519.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","volume":"13","author":"Ma","year":"2023","journal-title":"BMJ Open"},{"key":"2026010703055639000_3.2.e002519.33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/14740338.2024.2354885","article-title":"Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile","volume":"23","author":"Scheen","year":"2024","journal-title":"Expert Opin Drug Saf"}],"container-title":["BMJ Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjph-2024-002519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:06:38Z","timestamp":1767783998000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjpublichealth.bmj.com\/lookup\/doi\/10.1136\/bmjph-2024-002519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,7,22]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjph-2024-002519"],"URL":"https:\/\/doi.org\/10.1136\/bmjph-2024-002519","relation":{},"ISSN":["2753-4294"],"issn-type":[{"value":"2753-4294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}